CTOs on the Move

Immantics

www.immatics.com

 
Immatics Biotechnologies is a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer. Cancer immunotherapy is still severely constrained by the lack of novel targets. Immatics overcomes this by applying its target discovery engine XPRESIDENT® to identify and validate antigens specific to cancer cells. These antigens, also called Tumor-Associated Peptides (TUMAPs), are able to activate T cells which are responsible for identifying and destroying cancer cells. These well characterized TUMAPs can be used as targets for all of the most promising cancer immunotherapy approaches including Adoptive Cell Therapies (ACT), soluble T Cell Receptors (TCRs), Antibodies ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.immatics.com
  • 7000 Fannin Suite 2115, 2120
    Houston, TX USA 77030
  • Phone: 346.204.5400

Executives

Name Title Contact Details

Funding

Immantics raised $40.3M on 09/02/2015

Similar Companies

Evozyne

Evozyne is a data-driven evolution-based molecular engineering platform for building novel, application-specific proteins with advanced functionality.

Swift Biosciences

Swift Biosciences is a biotechnology company that is developing novel molecular biology technologies to better characterize and understand the genome. We are an energetic, highly innovative company focused on creating tools to advance the DNA sequencing sciences. Our products are designed to help customers analyze challenging samples that are often associated with translational work, including circulating, cell-free DNA and formalin-fixed, paraffin-embedded samples.

Raptor Pharmaceuticals

Raptor is a NASDAQ-listed biopharmaceutical company with the mission to develop and commercialize life-altering therapeutics that treat debilitating and often fatal diseases. Raptor`s lead product, PROCYSBI (cysteamine bitartrate) delayed-release capsules, received FDA approval on April 30, 2013. The Company anticipates receiving a determination from the EMA regarding its PROCYSBI marketing application in the European Union in the second half of 2013. Raptor’s product pipeline may advance therapeutic options for additional indications. Raptor`s management team consists of repeat entrepreneurs with the experience to build a successful company.

Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.

Greiner Bio One Inc

Greiner Bio One Inc is a Monroe, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.